Takeda Pharmaceutical Co Stock Profit Margin
| TAK Stock | USD 13.18 0.19 1.42% |
Takeda Pharmaceutical Co fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Stock. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical stock.
| Last Reported | Projected for Next Year | ||
| Net Profit Margin | 0.09 | 0.15 |
Takeda | Profit Margin |
Takeda Pharmaceutical Co Company Profit Margin Analysis
Takeda Pharmaceutical's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Takeda Pharmaceutical Profit Margin | 0.04 % |
Most of Takeda Pharmaceutical's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Takeda Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Takeda Pharmaceutical is extremely important. It helps to project a fair market value of Takeda Stock properly, considering its historical fundamentals such as Profit Margin. Since Takeda Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Takeda Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Takeda Pharmaceutical's interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Takeda Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Takeda Pharmaceutical Co has a Profit Margin of 0.0428%. This is 100.38% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The profit margin for all United States stocks is 103.37% lower than that of the firm.
Takeda Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takeda Pharmaceutical's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics of similar companies.Takeda Pharmaceutical is currently under evaluation in profit margin category among related companies.
Takeda Pharmaceutical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Takeda Pharmaceutical from analyzing Takeda Pharmaceutical's financial statements. These drivers represent accounts that assess Takeda Pharmaceutical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Takeda Pharmaceutical's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.5T | 3.2T | 2.7T | 3.4T | 3.9T | 4.7T | |
| Enterprise Value | 7.0T | 6.8T | 6.2T | 7.3T | 6.5T | 3.8T |
Takeda Fundamentals
| Return On Equity | 0.0276 | ||||
| Return On Asset | 0.0261 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 4.94 T | ||||
| Shares Outstanding | 3.14 B | ||||
| Shares Owned By Institutions | 2.66 % | ||||
| Number Of Shares Shorted | 8.12 M | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 4.03 T | ||||
| Gross Profit | 2.44 T | ||||
| EBITDA | 1.21 T | ||||
| Net Income | 317.04 B | ||||
| Cash And Equivalents | 533.53 B | ||||
| Cash Per Share | 208.91 X | ||||
| Total Debt | 4.38 T | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 1.18 X | ||||
| Book Value Per Share | 4,297 X | ||||
| Cash Flow From Operations | 977.16 B | ||||
| Short Ratio | 5.26 X | ||||
| Earnings Per Share | 0.37 X | ||||
| Price To Earnings To Growth | 3.23 X | ||||
| Target Price | 18.39 | ||||
| Number Of Employees | 49.09 K | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 41.9 B | ||||
| Total Asset | 13.96 T | ||||
| Retained Earnings | 1.54 T | ||||
| Working Capital | (83.98 B) | ||||
| Annual Yield | 0.05 % | ||||
| Five Year Return | 4.54 % | ||||
| Net Asset | 13.96 T | ||||
| Last Dividend Paid | 184.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink | |
| XLM | Stellar | |
| CRO | Cronos |
Check out Takeda Pharmaceutical Piotroski F Score and Takeda Pharmaceutical Altman Z Score analysis. Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Takeda Stock analysis
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.12) | Dividend Share 184 | Earnings Share 0.37 | Revenue Per Share 1.3 K | Quarterly Revenue Growth 0.013 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.